home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Collection of Education
/
collectionofeducationcarat1997.iso
/
HEALTH
/
MED9601.ZIP
/
M9610330.TXT
< prev
next >
Wrap
Text File
|
1996-01-30
|
3KB
|
44 lines
Document 0330
DOCN M9610330
TI Quantitative structural activity relationship study of
bis-tetraazacyclic compounds. A novel series of HIV-1 and HIV-2
inhibitors.
DT 9601
AU Joao HC; De Vreese K; Pauwels R; De Clercq E; Henson GW; Bridger GJ;
Sandoz Research Institute, Vienna, Austria.
SO J Med Chem. 1995 Sep 15;38(19):3865-73. Unique Identifier : AIDSLINE
MED/96009810
AB This work describes a study of quantitative structural activity
relationships (QSAR) of bis-tetraazamacrocyclic compounds. These
compounds represent a novel class of very potent and selective anti-HIV
inhibitors, with a new mode of action. The QSAR study correlates
structural features of the compounds with anti-HIV activity, resulting
in a model which has a high predictive capacity (predictive r2 = 0.79).
This predictive model will be of major importance for the design of new
anti-HIV inhibitors of this class. Use is made of partial least-squares
(PLS) analysis, with the novelty being that structural features derived
by inclusion of all sterically allowed conformations for each molecule
are included in the analysis. PLS analysis was made of descriptors,
including structural parameters, macrocyclic ring size, metal chelating
ability, etc., and those features necessary for the observed antiviral
activities of these compounds were deduced from the models. Since all
sterically allowed conformations are included in the analysis, the
flexibility of the molecules is also taken into account. In addition, a
correlation is found (indicated by a predictive r2 value of 0.61)
between inhibition of HIV-1 (HIV-2) and syncytium formation inhibition
in the presence of bis-cyclam analogues, leading to the suggestion of a
common target, namely, gp120, being involved in both inhibition of virus
replication and syncytium formation.
DE Antiviral Agents/*CHEMISTRY/CHEMICAL SYNTHESIS/*PHARMACOLOGY Computer
Simulation Drug Design Giant Cells Heterocyclic
Compounds/*CHEMISTRY/CHEMICAL SYNTHESIS/ *PHARMACOLOGY Human HIV
Envelope Protein gp120/METABOLISM HIV-1/*DRUG EFFECTS/PHYSIOLOGY
HIV-2/*DRUG EFFECTS/PHYSIOLOGY Least-Squares Analysis Models, Chemical
Molecular Conformation Molecular Structure Software
Structure-Activity Relationship Virus Replication/DRUG EFFECTS JOURNAL
ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).